Amcor stock falls after Raymond James reiterates Market Perform rating
ANN ARBOR, MI—Johnny Powers, a director at Zomedica Corp. (NYSEAMERICAN:ZOM), has recently increased his holdings in the company by purchasing a significant amount of common stock. According to a filing with the Securities and Exchange Commission, Powers acquired a total of 500,000 shares on March 17, 2025. The transactions were executed at prices ranging from $0.065 to $0.07 per share, amounting to a total value of $33,650. The timing is notable as InvestingPro data shows the stock’s RSI indicates oversold territory, with shares down nearly 34% over the past year.
The acquisitions reflect Powers’ direct ownership in the company, with the shares bought on the open market. Following these transactions, Powers’ total holdings in Zomedica have risen to 2,925,000 shares. The company maintains a strong balance sheet, with cash reserves exceeding debt levels.
Zomedica Corp., based in Ann Arbor, Michigan, is a company within the pharmaceutical preparations industry, focusing on veterinary health solutions. The recent stock purchases by Powers could signal confidence in the company’s future prospects, although the reasons behind the transactions were not disclosed in the filing. According to InvestingPro, the company maintains a "Fair" overall financial health score, with particularly strong liquidity metrics. Subscribers can access 12 additional ProTips and a comprehensive analysis through the Pro Research Report, providing deeper insights into Zomedica’s financial position and growth potential.
In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported its fourth-quarter 2024 earnings, showcasing a revenue of $7.9 million, which represents an 8% increase compared to the previous year. Despite a net loss of $7.2 million, the company maintained strong gross margins and a robust cash position with $71.4 million in liquidity. Zomedica’s full-year 2024 revenue reached a record $27.3 million, supported by growth in both therapeutic devices and diagnostic segments. The company’s strategic focus on expanding its presence in the veterinary and equine markets contributed to this growth. Additionally, Zomedica has been exploring international expansion, with new distribution agreements in Europe and the Middle East. In terms of analyst activity, the company has not recently experienced any significant upgrades or downgrades. Zomedica plans to continue its expansion into international territories and aims to reach cash flow breakeven at a $50 million run rate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.